Combination of Radiotherapy and SHR-1210 to Treat Patients With ESCC

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 19, 2017

Primary Completion Date

July 20, 2018

Study Completion Date

November 1, 2019

Conditions

Esophageal Cancer

Interventions

DRUG

SHR-1210

SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.

Trial Locations (1)

Department of Radiation Oncology, Tianjin Medical University Cancer Hospital, Tianjin

All Listed Sponsors

collaborator

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

lead

Tianjin Medical University Cancer Institute and Hospital

OTHER

NCT03222440 - Combination of Radiotherapy and SHR-1210 to Treat Patients With ESCC | Biotech Hunter | Biotech Hunter